What is new in the treatment of peripheral T-cell lymphomas in the Czech Republic
Authors:
M. Filipová; A. Janíková
Authors‘ workplace:
Interní hematologická a onkologická klinika FN Brno
Published in:
Transfuze Hematol. dnes,29, 2023, No. 4, p. 227-239.
Category:
Review/Educational Papers
doi:
https://doi.org/10.48095/cctahd2023prolekare.cz18
Overview
Peripheral T-cell lymphomas (PTCL) belong to the group of non-Hodgkin’s lymphomas, characterized by considerable heterogeneity and, compared to B-lymphomas, by poorer treatment response, limited treatment options, and high mortality. Statistical data concerning patients with PTCL, including those collected in the Czech Republic, clearly point to the necessity of searching for new strategies to improve the prognosis of patients with PTCL. The heterogeneity of T-lymphomas and the lack of understanding of their pathogenesis have led to inaccurate and imperfect diagnoses and insufficient development of targeted and effective treatments. The spectrum of newly identified genomic defects affecting the correct function of T-cell signalization, which plays a key role in the pathogenesis of PTCL, is broadening. Thus, there is hope for the potential discovery of new therapeutic agents and the development of new targeted treatment strategies, which are currently intensively tested on preclinical models and in clinical studies. New therapeutic agents, their use in routine clinical practice, and their combination with already-established therapeutic strategies could represent key factors in improving the outcomes of patients with PTCL.
Keywords:
peripheral T-lymphomas – brentuximab vedotin – HDAC inhibitors – ALK inhibitors
Sources
1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36 (7): 1720–1748. doi: 10.1038/s41375- 022-01620-2.
2. Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020; 20 (6): 323–342. doi: 10.1038/s415 68-020-0247-0.
3. Janikova A, Chloupkova R, Campr V, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019; 98 (8): 1961–1972. doi: 10.1007/s00277-019-03694-y.
4. Petrich AM, Helenowski IB, Bryan LJ, Rozell SA, Galamaga R, Nabhan C. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. Br J Haematol. 2015; 168 (5): 708–718. doi: 10.1111/bjh.13202
5. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014; 124 (10): 1570–1577. doi: 10.1182/blood- 2014-04-573089.
6. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry: Clinical trials and prognostic indices in PTCL. Hematol Oncol. 2015; 33 (4): 120–128. doi: 10.1002/hon.2153.
7. Wudhikarn K, Bennani NN. How to sequence therapies in peripheral T cell lymphoma. Curr Treat Options Oncol. 2021; 22 (9): 74. doi: 10.1007/s11864-021-00873-w.
8. Saleh K, Michot JM, Ribrag V. Updates in the treatment of peripheral T-cell lymphomas. J Exp Pharmacol. 2021; 13: 577–591. doi: 10.2147/JEP.S262344.
9. Gleeson M, Peckitt C, Cunningham D, et al. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. Leuk Lymphoma. 2018; 59 (7): 1586–1595. doi: 10.1080/10428194.2017.1393671.
10. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010; 116 (18): 3418–3425. doi: 10.1182/blood-2010-02-270785.
11. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; 15 (10): 1467–1475. doi: 10.1093/annonc/ mdh392.
12. Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95: VIP-rABVD versus CHOP/21 in Newly Diagnosed PTCL. Br J Haematol. 2010; 151 (2): 159–166. doi: 10.1111/j.1365-2141.2010.08329.x.
13. Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019; 133 (15): 1664–1676. doi: 10.1182/blood- 2018-09-872549.
14. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology (Phila). 2018; 50 (1): 74–87. doi: 10.1016/j.pathol.2017.09.006.
15. Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013; 87 (2): 146–171. doi: 10.1016/j.critrevonc. 2012.12.009.
16. Luminari S, Skrypets T. What’s new in peripheral T‐cell lymphomas. Hematol Oncol. 2021; 39 (S1): 52–60. doi: 10.1002/hon.2846.
17. Foster C, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Research. 2020; 9: 1091. doi: 10.12688/f1000research.22257.1
18. Escalón MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The M. D. Anderson Cancer Center experience. Cancer. 2005; 103 (10): 2091–2098. doi: 10.1002/cncr.20999.
19. DuPage M, Bluestone JA. Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease. Nat Rev Immunol. 2016; 16 (3): 149–163. doi: 10.1038/nri.2015.18.
20. Zain JM. Aggressive T‐cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am J Hematol. 2019; 94 (8): 929–946. doi: 10.1002/ajh.25513.
21. Mulvey E, Ruan J. Biomarker-driven management strategies for peripheral T cell lymphoma. J Hematol Oncol. 2020; 13 (1): 59. doi: 10.1186/s13045-020-00889-z.
22. Janikova A, Michalka J, Chloupkova R, et al. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). Ann Hematol. 2022; 101 (4): 789–798. doi: 10.1007/s00277-022-04759-1.
23. Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014; 123 (19): 3007–3015. doi: 10.1182/blood-2013-12-544809.
24. Zhang Y, Lee D, Brimer T, Hussaini M, Sokol L. Genomics of peripheral T-cell lymphoma and its implications for personalized medicine. Front Oncol. 2020; 10: 898. doi: 10.3389/fonc. 2020.00898.
25. Dürkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000; 190 (5): 613–618. doi: 10.1002/ (SICI) 1096-9896 (2000 04) 190: 5<613:: AID-PATH559>3.0.CO; 2-0.
26. van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017; 7 (9): e603–e603. doi: 10.1038/bcj.2017.85.
27. Salas MQ, Climent F, Tapia G, et al. Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers. 2020; 25 (1): 69–75. doi: 10.1080/1354750X.2019.1691656.
28. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of ap II study. J Clin Oncol. 2012; 30 (18): 2190–2196. doi: 10.1200/JCO. 2011.38.0402.
29. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003; 102 (4): 1458–1465. doi: 10.1182/blood-2003-01-0039.
30. Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. The Lancet. 2019; 393 (10168): 229–240. doi: 10.1016/S0140-6736 (18) 32984-2.
31. Shea L, Mehta-Shah N. Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma. Curr Hematol Malig Rep. 2020; 15 (1): 9–19. doi: 10.1007/s11899-020-00561-w.
32. Oberic L, Delzor F, Protin C, et al. Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma. J Oncol Pharm Pract. 2021; 27 (7): 1730–1735. doi: 10.1177/1078155220968615.
33. Van de Wyngaert Z, Coppo P, Cervera P, et al. Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma. Eur J Haematol. 2021; 106 (4): 467–472. doi: 10.1111/ejh.13568.
34. Herrera AF, Zain J, Savage KJ, et al. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas. Blood. 2021; 138 (Suppl 1): 133–133. doi: 10.1182/blood-2021-151105.
35. Zhang P, Zhang M. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenetics. 2020; 12 (1): 169. doi: 10.1186/s13148-020-00962-x
36. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009; 27 (32): 5459–5468. doi: 10.1200/JCO. 2009.22.1291.
37. O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015; 33 (23): 2492–2499. doi: 10.1200/ JCO.2014.59.2782.
38. Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014; 7 (1): 11. doi: 10.1186/1756-8722-7-11.
39. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30 (6): 631–636. doi: 10.1200/JCO.2011.37.4223.
40. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011; 117 (22): 5827–5834. doi: 10.1182/blood-2010-10-312603.
41. Bachy E, Camus V, Thieblemont C, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022; 40 (3): 242–251. doi: 10.1200/JCO.21.01815.
42. Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015; 168 (6): 811–819. doi: 10.1111/bjh.13222.
43. Gisselbrecht C, Sibon D. New perspectives in the therapeutic approach of peripheral T-cell lymphoma. Curr Opin Oncol. 2018; 30 (5): 285–291. doi: 10.1097/CCO.0000000000000469.
44. Marchi E, O’Connor OA. The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management. CA Cancer J Clin. 2020; 70 (1): 47–70. doi: 10.3322/caac.21589.
45. Lemonnier F, Dupuis J, Sujobert P, et al. Treatment with 5-azacytidine induces a sustain- ed response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018; 132 (21): 2305–2309. doi: 10.1182/blood-2018-04-840538.
46. Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021; 137 (16): 2161–2170. doi: 10.1182/blood.2020009004.
47. O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL Study. J Clin Oncol. 2011; 29 (9): 1182–1189. doi: 10.1200/JCO. 2010.29.9024.
48. Ng SY, Jacobsen ED. Peripheral T-cell lymphoma. Hematol Oncol Clin North Am. 2019; 33 (4): 657–668. doi: 10.1016/j.hoc.2019.04. 002.
49. Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018; 131 (4): 397–407. doi: 10.1182/blood-2017-09-806737.
50. Bhurani M, Admojo L, Van Der Weyden C, et al. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Leuk Lymphoma. 2021; 62 (2): 330–336. doi: 10.1080/10428194.2020.1827241.
51. Cederleuf H, Bjerregård Pedersen M, Jerkeman M, Relander T, d’Amore F, Ellin F. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. Br J Haematol. 2017; 178 (5): 739–746. doi: 10.1111/bjh.14740.
52. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision medicine takes on drug resistance. Cancer Discov. 2017; 7 (2): 137–155. doi: 10.1158/2159-8290.CD-16-1123.
53. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14 (6): 472–480. doi: 10.1016/ S1470-2045 (13) 70095-0.
54. Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial. Cancer Sci. 2020; 111 (12): 4540–4547. doi: 10.1111/cas.14671.
55. Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021; 22 (7): 3464. doi: 10.3390/ijms22073 464.
56. Seiler T, Hutter G, Dreyling M. The emerging role of PI3K inhibitors in the treatment of hematological malignancies: preclinical data and clinical progress to date. Drugs. 2016; 76 (6): 639–646. doi: 10.1007/s40265-016-0565-4.
57. Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-d, g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018; 131 (8): 888–898. doi: 10.1182/blood-2017-08-802470.
58. Huen A, Haverkos BM, Zain J, et al. Phase I/Ib study of tenalisib (RP6530), a dual PI3K d/g inhibitor in patients with relapsed/refractory T-cell Llmphoma. Cancers. 2020; 12 (8): 2293. doi: 10.3390/cancers12082293.
59. Shouse G, Nikolaenko L. Targeting the JAK/STAT pathway in T cell lymphoproliferative disorders. Curr Hematol Malig Rep. 2019; 14 (6): 570–576. doi: 10.1007/s11899-019-00 545-5.
60. Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021; 138 (26): 2828–2837. doi: 10.1182/blood.20210 13379.
61. Hamlin PA, Cheson BD, Farber CM, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL). J Clin Oncol. 2018; 36 (15Suppl): 7511–7511. doi: 10.1200/JCO.2018.36.15suppl.7511.
62. Cencini E, Fabbri A, Mecacci B, Bocchia M. Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas. World J Clin Oncol. 2021; 12 (10): 882–896. doi: 10.5306/wjco.v12.i10.882.
63. Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011; 52 (8): 1585–1588. doi: 10.3109/10428194.2011.573 031.
64. Morschhauser F, Fitoussi O, Haioun C, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. Eur J Cancer. 2013; 49 (13): 2869–2876. doi: 10.1016/ j.ejca.2013.04.029.
65. Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma: lenalidomide therapy for T-cell lymphoma. Cancer. 2015; 121 (5): 716–723. doi: 10.1002/cncr.29103.
66. Lemonnier F, Safar V, Beldi-Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021; 5 (2): 539–548. doi: 10.1182/bloodadvances.2020003 081.
67. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377 (26): 2531–2544. doi: 10.1056/NEJM oa1707447.
68. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380 (1): 45–56. doi: 10.1056/NEJMoa 1804980.
69. Rogers AM, Brammer JE. Hematopoietic cell transplantation and adoptive cell therapy in peripheral T cell lymphoma. Curr Hematol Malig Rep. 2020; 15 (4): 316–332. doi: 10.1007/s118 99-020-00590-5.
70. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006; 24 (16): 2472–2479. doi: 10.1200/JCO.2005.03.6327.
71. Wu Y, Chen D, Lu Y, et al. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther. 2022; 29 (2): 167–177. doi: 10.1038/s41417-021-00295-8.
72. Maciocia PM, Wawrzyniecka PA, Philip B, et al. Targeting the T cell receptor b-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23 (12): 1416–1423. doi: 10.1038/nm.4444.
73. Cwynarski K, Iacoboni G, Tholouli E, et al. First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed/refractory TRBC1-positive peripheral T-cell lymphoma. Blood. 2022; 140 (Suppl 1): 10316–10317. doi: 10.1182/blood-2022-165971.
74. Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R. Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Ann Hematol. 2023; 102 (1): 13–29. doi: 10.1007/ s00277-022-05054-9.
75. Barr PM, Li H, Spier C, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015; 33 (21): 2399–2404. doi: 10.1200/JCO. 2014.60.6327.
76. O’Connor OA, Özcan M, Jacobsen ED, et al. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol. 2019; 37 (8): 613–623. doi: 10.1200/JCO.18.00899.
77. Strati P, Nastoupil LJ, Davis RE, et al. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020; 105 (1): e26–e28. doi: 10.3324/haematol.2019.220012.
78. Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. J Clin Oncol. 2020; 38 (1): 20–28. doi: 10.1200/JCO.19.01056.
79. Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017; 129 (17): 2437–2442. doi: 10.1182/blood-2016-12-756 841.
80. Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia–lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018; 378 (20): 1947–1948. doi: 10.1056/NEJMc1803181.
81. Rauch DA, Conlon KC, Janakiram M, et al. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood. 2019; 134 (17): 1406–1414. doi: 10.1182/blood.2019002038.
82. Molica S. Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia. Int J Hematol Oncol. 2020; 9 (4): IJH31. doi: 10.2217/ijh-2020-0010.
83. Gangat N, Tefferi A. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. Blood Cancer J. 2020; 10 (11): 122. doi: 10.1038/s41408-020-00388-x.
84. Ballotta L, Zinzani PL, Pileri S, et al. Venetoclax shows low therapeutic activity in BCL2-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Front Oncol. 2021; 11: 789891. doi: 10.3389/fonc.2021.789891.
85. Adcetris souhrn údajů o přípravku [online]. [cit. 2023-06-11]. Dostupné z: https: //prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0193 650.
86. Beleodaq highlights of prescribing information [online]. [cit. 2023-06-11]. Dostupné z: https: //www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf.
87. Istodax highlights of prescribing information [online]. [cit. 2023-06-11]. Dostupné z: https: //www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf.
88. Vidaza souhrn údajů o přípravku [online]. [cit. 2023-06-11]. Dostupné z: https: //prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0500947.
89. Folotyn highlights of prescribing information [online]. [cit. 2023-06-11]. Dostupné z: https: //www.clinicaltrials.gov/.
90. Xalkori souhrn údajů o přípravku [online]. [cit. 2023-06-11]. Dostupné z: https: //prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0193646.
91. Alecensa souhrn údajů o přípravku [online]. [cit. 2023-06-11]. Dostupné z: https: // prehledy.sukl.cz/prehled_leciv.html#/detail- reg/0219362.
92. Copiktra souhrn údajů o přípravku [online]. [cit. 2023-06-11]. Dostupné z: https: // prehledy.sukl.cz/prehled_leciv.html#/detail- reg/0255061.
93. Revlimid souhrn údajů o přípravku [online]. [cit. 2023-06-11]. Dostupné z: https: //pre- hledy.sukl.cz/prehled_leciv.html#/detail-reg/ 0028937.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2023 Issue 4
Most read in this issue
- What is new in the treatment of peripheral T-cell lymphomas in the Czech Republic
- Role of NK cell receptors in allogeneic stem cell transplantation in patients with acute myeloid leukaemia
- Accessibility of red blood cell components in the Czech Republic 2019–2021 – questionnaire-based survey of Blood Transfusion Services